Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report

Haruki Shida¹, Nobuhiro Hashimoto², Yoshihiro Kusunoki¹, Fumihiko Hattanda¹, Yayoi Ogawa³, Terumasa Hayashi², Daigo Nakazawa¹, Sakiko Masuda⁴, Utano Tomaru⁵ and Akihiro Ishizu⁴*

Abstract

Background: Neutrophil extracellular traps (NETs) are web-like DNA decorated with antimicrobial proteins, such as myeloperoxidase (MPO), which are extruded from activated neutrophils. Although NETs are essential in innate immunity, an excessive formation of NETs has adverse effects, e.g., induction of anti-neutrophil cytoplasmic antibody (ANCA), to the hosts. Since ANCA can induce NET formation in the primed neutrophils, a positive feedback loop can be formed between NETs and ANCA, which is called “ANCA-NETs vicious cycle.”

Case presentation: A 79-year-old Japanese woman developed hydralazine-induced pauci-immune necrotizing crescentic glomerulonephritis with MPO-ANCA. Although the illness improved after cessation of hydralazine, MPO-ANCA-associated vasculitis relapsed 16 months later. Remission was achieved 5 months after beginning of administration of prednisone. In order to determine the involvement of ANCA-NETs vicious cycle in this patient, we examined NET degradation and induction activities in sera obtained at the disease onset (Serum A; MPO-ANCA, 107 IU/ml), at relapse (Serum B; MPO-ANCA, 195 IU/ml), at 3 months after treatment (Serum C; MPO-ANCA, 4.5 IU/ml), and at remission (Serum D; MPO-ANCA, 2.4 IU/ml). NET degradation activity was low in all sera. NET induction activity was high in Sera A, B, and C but not in D. Additionally, we demonstrated the presence of anti-NET antibody (ANETA) in Sera B and C but not in A or D.

Conclusions: The collective findings suggest NET induction potential of ANETA in the present patient and that the ANETA could contribute to the enhancement of NETs resulting in amplification of the ANCA-NETs vicious cycle.

Keywords: ANCA-associated vasculitis (AAV), Neutrophil extracellular traps (NETs), ANCA-NETs vicious cycle, Anti-NET antibody (ANETA)

Background

Neutrophil extracellular traps (NETs) are web-like DNA decorated with antimicrobial proteins, such as myeloperoxidase (MPO) and proteinase 3 (PR3), which are extruded from activated neutrophils [1]. NETs can trap microorganisms by the web-like DNA and kill them using the antimicrobial proteins. Chronic granulomatous disease (CGD) patients who cannot generate NETs are indeed susceptible to bacterial and fungal infections, and it was shown that restoration of NET formation in CGD resulted in resistance to such infections [2]. Although NET formation is regarded as an essential event in the innate immunity, an excessive formation of NETs can induce vascular endothelial cell damage and thrombosis resulting in the development of microvascular disorders [3, 4]. In addition, disordered regulation of NETs has been suggested to be involved in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE) [5] and anti-thyroid drug propylthiouracil.
ANCA-NETs vicious cycle.

possibility of its contribution to the amplification of the present patient could enhance NET formation and the MPO-ANCA. We demonstrated that ANETA in the antibody (ANETA) was detected in the sera together with occurred in the present patient. During relapse, anti-NET cially in a situation without re-medication of the causative relapse of drug-induced MPO-AAV is quite rare, espe-

16 months after the first diagnosis. To our knowledge, the MPO-AAV relapsed regardless of non-usage of the drug immediate cessation of the causative drug, but

MPO-ANCA can induce NET formation in TNF-α-primed neutrophils [10].

One of the most important regulators of NETs is serum DNase I [5]. We have demonstrated that PTU-induced DNase I-resistant NETs can lead to the production of MPO-ANCA and subsequent development of SVV [6]. We have further demonstrated that the serum DNase I activity in patients with MPO-AAV is significantly lower than that in healthy controls [11]. Based on these findings, we have suggested that ANCA-NETs vicious cycle is involved in the pathogenesis of MPO-AAV.

We herein demonstrate a patient with hydralazine-induced MPO-AAV. The disease activity was controlled by immediate cessation of the causative drug, but MPO-AAV relapsed regardless of non-usage of the drug 16 months after the first diagnosis. To our knowledge, the relapse of drug-induced MPO-AAV is quite rare, especially in a situation without re-medication of the causative drug. We suspected that a certain immunological event occurred in the present patient. During relapse, anti NET antibody (ANETA) was detected in the sera together with MPO-ANCA. We demonstrated that ANETA in the present patient could enhance NET formation and the possibility of its contribution to the amplification of the ANCA-NETs vicious cycle.

Case presentation

A 79-year-old Japanese woman with a weight of 72 kg who has been maintained on anti-hypertensive drugs, including hydralazine, for more than 10 years, was advised on acute onset of proteinuria and microscopic hematuria by her family doctor. At this time, her serum creatinine (Cr) level was within normal range (0.8 mg/dl). One month later, however, the Cr level was elevated to 1.6 mg/dl. Therefore, she was referred to our hospital for admission.

On admission, vital signs revealed body temperature of 36.9 °C, blood pressure of 150/70 mmHg, and pulse rate of 80 per minute. The white blood cell count was 8700/μl with 2.0% eosinophils, red blood cell count was 307 × 10^6/μl, and platelet count was 26.6 × 10^4/μl. The following values indicated renal dysfunction; blood urea nitrogen: 25.0 mg/dl, Cr: 1.9 mg/dl, urinary protein: 2.5 g/day, and the presence of microscopic hematuria. Dysmorphic red blood cells were noted in the urine sample microscopically. In the serum, MPO-ANCA was 107 IU/ml (normal limit, 3.5 IU/ml), whereas C-reactive protein (CRP) was 0.2 mg/dl. PR3-ANCA and other ANCAs, including anti-elastase and anti-lactoferrin antibodies, were negative. The titer of anti-nuclear antibody (ANA) was less than 1:40. Anti-DNA antibody was negative. Complement values were as follows: C3 162.2 mg/dl (normal range, 71–135 mg/dl) and C4 37.7 mg/dl (normal range, 11–34 mg/dl). Renal biopsy revealed pauci-immune necrotizing crescentic glomerulonephritis (Fig. 1a).

Hydralazine-induced MPO-AAV was considered regardless of absence of skin involvement, elastase- and lactoferrin-ANCAs, anti-nuclear and anti-DNA antibodies, and hypocomplementemia, which are usually observed in the disease [12]. By discontinuation of the causative drug, the serum Cr level decreased gradually. At 10 months later, the serum Cr and MPO-ANCA levels recovered to 1.1 mg/dl and 13 IU/ml, respectively. Proteinuria and microscopic hematuria also disappeared. Since the clinical course was consistent with hydralazine-induced MPO-AAV and the serum CRP level was not high throughout the clinical course, no additional medication was administered.

After another 6 months of observation, the serum Cr and MPO-ANCA levels were re-elevated (Cr, 2.0 mg/dl; MPO-ANCA, 195 IU/ml) and proteinuria and microscopic hematuria were re-appeared. The titer of ANA was 1:40. Other ANCAs, including PR3-ANCA, and anti-DNA antibody were negative even at this time. Complement values were as follows: C3 149.4 mg/dl and C4 38.5 mg/dl. Renal biopsy was performed again and revealed cellular crescents in some glomeruli (Fig. 1b).

These findings suggested the relapse of MPO-AAV. Since she had fever (38.3 °C), and the serum CRP level was elevated to 10.0 mg/dl at this time, administration of 30 mg prednisone (0.5 mg/kg body weight) was initiated. The illness improved rapidly, and remission was achieved 5 months after the beginning of treatment. The patient has remained in remission thereafter (Table 1).

Serological analyses

This study was approved by the Ethical Committee of Osaka General Medical Center (Permission No. 29-C0313) and the Ethical Committee of Faculty of Health Sciences, Hokkaido University (Permission No. 15–90). After acquisition of written informed consent from the patient, serum samples were obtained at the disease onset (Serum A; MPO-ANCA, 107 IU/ml), at relapse (Serum B; MPO-ANCA, 195 IU/ml), at 3 months
after treatment (Serum C; MPO-ANCA, 4.5 IU/ml), and at remission (Serum D; MPO-ANCA, 2.4 IU/ml).

To assess the involvement of NETs in the pathophysiology of this patient, we determined the NET degradation activity in the serum samples at first. In brief, peripheral blood neutrophils from a healthy volunteer were seeded in slide chambers (1 × 10^6/ml), incubated for 15 min at 37 °C, and then made to react with 100 nM phorbol myristate acetate (PMA; Sigma-Aldrich, St. Louis, MO) for 3 h at 37 °C. We have confirmed that this stimulation induces NETs conspicuously [11]. After washing with PBS, the cells were incubated in 10% Serum A, B, C, or D for 6 h at 37 °C. For positive control, 10% serum of a healthy volunteer (49 years old, male) was employed. This sample exhibited the average value for NET degradation in our previous study [11]. To stop the serum nuclease activity, 2 mM EDTA was added, and then the remaining cells on the slides were fixed with 4% paraformaldehyde (PFA) followed by mounting with the solution containing DAPI. Photomicrographs (magnification, ×200) were taken randomly under a fluorescent microscope (6 fields/well of chamber slides), and then the residual NET area was determined using Image J software. NET degradation rate (%) was calculated as follows; {(residual NET area, incubated with PBS) – (residual NET area, incubated with serum) / (residual NET area, incubated with PBS)} × 100. As a result, the NET degradation activity was entirely low in Sera A, B, C, and D compared with the healthy control (Fig. 1c). Correspondingly, the DNase I activity as determined using ELISA kit (Orgentec GmbH, Mainz, Germany) was low in Sera A (21.7%), B (28.3%), C (22.8%), and D (33.5%) compared with the healthy controls {mean ± standard deviation (SD), 52.6 ± 12.1%}.

Next, we determined the NET induction activity of IgG, which was isolated from the serum samples, using immunoabsorbent columns (Protein G HP SpinTrap, GE Healthcare, Tokyo, Japan). Contamination of endotoxin in the IgG samples was ruled out using the Limulus test kit (Wako Pure Chemical, Osaka, Japan). Peripheral blood neutrophils from a healthy volunteer were seeded in slide chambers (1 × 10^6/ml), pre-treated with 5 ng/ml TNF-α for 15 min at 37 °C to express MPOs on the cell surface, and then made to react with 250 μg/ml of the IgG samples. Serum IgG samples from a 65-year-old woman patient with MPO-AAV (MPO-ANCA, 93.2 IU/ml) and the healthy volunteer were employed as positive and negative controls, respectively. These samples exhibited the average values for NET induction in our previous study [11]. After incubation for 3 h at 37 °C, the supernatants were removed and the remaining cells on the slides were fixed with 4% PFA. Finally, the remaining cells were mounted with the DAPI-containing solution. Photomicrographs (magnification, ×200) were taken.
randomly under a fluorescent microscope (6 fields/well of chamber slides), and then the rates of NET-forming neutrophils were determined using ImageJ software. As a result, the NET induction activity was high in Sera A, B, and C, whereas that in Serum D was equivalent to the healthy control (Fig. 1d).

Lastly, we conducted immunofluorescent (IF) tests to determine the presence of ANETA in the serum samples. Briefly, peripheral blood neutrophils from a healthy volunteer were seeded in slide chambers (1 × 10^6/ml), incubated for 15 min at 37 °C, and then made to react with 20 nM PMA for 2 h at 37 °C. After washing with PBS, the cells were fixed with 4% PFA, and then made to react with 250 μg/ml of the IgG samples for 1 h at 37 °C. After washing with PBS, the cells were next allowed to react with 1:5000 dilution of FITC-conjugated anti-human IgG antibodies for 1 h at 37 °C followed by mounting with the solution containing DAPI. As shown in Fig. 2, ANCA was detected in Sera A and B but not in Sera C or D; thus, these findings were consistent with the ELISA titers of MPO-ANCA. On the other hand, ANETA was detected in Sera B and C but not in Serum A or D.

**Discussion**

We are demonstrating a patient who developed hydralazine-induced MPO-AAV. At the onset of the disease, necrotizing crescentic glomerulonephritis occurred with a high titer of MPO-ANCA (107 IU/ml). By cessation of hydralazine, the serum Cr level and MPO-ANCA titer decreased gradually. These findings suggest the pathogenicity of MPO-ANCA induced by hydralazine in the present patient.

Although the patient recovered from the illness by discontinuation of hydralazine, MPO-ANCA remained at the titer of 13 IU/ml 10 months later. Afterwards, MPO-AAV relapsed regardless of non-usage of hydralazine 16 months after the first diagnosis. It is speculated that the persistent NETs could lead to the re-elevation of MPO-ANCA in the present patient according to the following observations. 1) The baseline potential of NET degradation also represented by DNase I activity in the serum was low. 2) MPO-ANCA has been shown to induce NETs [10]. 3) The excessive formation of NETs has been shown to lead to MPO-ANCA production [6, 13]. These are consistent with the concept of the ANCA-NETs vicious cycle in MPO-AAV [11].

---

**Table 1 Medical History Timeline**

| AAV clinical course               | Months after diagnosis | MPO-ANCA (IU/ml) | Serum |
|-----------------------------------|------------------------|------------------|-------|
| Disease on set, Diagnosis         | 0                      | 107              | A     |
| Cessation of hydralazine          | 10                     | 13               | –     |
| Cessation of hydralazine, Relapse | 16                     | 195              | B     |
| Administration of prednisone      | 19                     | 4.5              | C     |
| Administration of prednisone, Remission | 21                 | 2.4              | D     |

---

**Fig. 2** Detection of ANETA. Under the experimental condition, approximately 40% of neutrophils formed NETs (arrowheads in DAPI panels), whereas the others sustained the cell morphology (asterisks in DAPI panels). ANCA was detected in Sera A and B (asterisks in FITC panels) but not in Sera C or D. ANETA was detected in Sera B and C (arrowheads in FITC panels) but not in Sera A or D. Representative photomicrographs are shown.
In addition to MPO-ANCA, ANETA was detected in the serum at relapse of MPO-AAV. Interestingly, NET induction potential of IgG samples derived from the serum at 3 months after treatment (Serum C, ANCA−/ANETA+) in IF test was high. Therefore, these findings suggest NET induction potential of ANETA in the present patient. ANETA possibly cooperates with MPO-ANCA to amplify the ANCA-NETs vicious cycle and contributes to relapse of the disease. Although this hypothesis should be confirmed by future studies, the concept is consistent with the recent report of in vivo demonstration of NETs in patients with hydralazine-induced AAV [14].

Currently, antigens of ANETA remain unrevealed. MPO is a component of NETs; however, MPO-ANCA in Serum A did not bind to NETs in the IF test. This finding suggests the masking of the MPO epitope in the NETs, which is recognized by MPO-ANCA in Serum A. On the contrary, IgG in Serum C was bound to NETs but not to neutrophils that conserved their morphology. The collective findings suggest the difference of ANETA from MPO-ANCA, though the possibility that ANETA recognizes the modified MPO cannot be ruled out for the present. In addition, Roth et al. have demonstrated that the anti-MPO peptide (amino acids 447–459) antibody is masked by the ceruloplasmin derivative in serum samples [15]. Therefore, the possible identity of the ANETA and anti-MPO peptide (amino acids 447–459) antibody cannot be ruled out, either.

Hakkim et al. demonstrated that anti-DNA antibodies were detected as ANETA in some SLE patients and suggested that these antibodies could interfere with the DNase I action resulting in the impaired regulation of NETs [5]. Since anti-nuclear and anti-DNA antibodies were not detected during the clinical course, ANETA in the present patient was different from autoantibodies against nuclear components.

The best used reagent to induce NETs is PMA, which activates the Raf-MEK-ERK cascade, NADPH oxidase-dependent production of ROS, and receptor-interacting protein kinase/mixed lineage kinase domain-like-mediated signals [16, 17]. In this pathway, peptidylarginine deiminase 4-dependent citrullination of histones induces decondensation of DNA resulting in a mixture of DNA and antimicrobial proteins, which are contained originally in intracytoplasmic granules [18]. Therefore, these substances are extruded from the ruptured plasma membrane. It is conceivable that molecules are modified in NET-forming neutrophils resulting in alteration of their antigenicity from the unstimulated condition. Accordingly, we have to consider the possibility that epitopes of degraded and/or complexed molecules are recognized by ANETA.

Furthermore, ANETA probably includes various antibodies that demonstrate diverse specificity and functions, e.g., inhibitory action against DNase I and NET induction property. Further studies are needed to determine the specificity and significance of ANETA.

Conclusion
Through the experience gained from the management of this patient, we have learned that ANETA is worthy of attention for understanding the pathophysiology of neutrophil-related autoimmune diseases, especially AAV.

Abbreviations
AAV: ANCA-associated vasculitis; ANA: Anti-nuclear antibody; ANCA: Anti-neutrophil cytoplasmatic antibody; ANETA: Anti-NET antibody; CGD: Chronic granulomatous disease; Cr: Creatinine; CRP: C-reactive protein; IF: Immunofluorescent; Ig: Immunoglobulin; MPO: Myeloperoxidase; NETs: Neutrophil extracellular traps; PFA: Paraformaldehyde; PR3: Proteinase 3; PTU: Propylthiouracil; ROS: Reactive oxygen species; SLE: Systemic lupus erythematosus; SV: Small vessel vasculitis; TNF: Tumor necrosis factor

Acknowledgements
This work was supported by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant number 26293082), a grant from the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and a grant from the Japan Agency for Medical Research and Development (grant number 15ek0109121).

Availability of data and materials
Data regarding the case report belong to clinical and laboratory charts stored in the hospital repository and cannot be shared.

Authors’ contributions
NH and TH took care of the patient. YO is a renal pathologist who helped diagnosis of the patient. HS, YK, and FH performed in vitro assays. HS, NH, YK, FH, DN, SM, UT and AI analyzed the data. UT and AI wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Ethical Committee of Osaka General Medical Center (Permission No. 29-C0313) and the Ethical Committee of Faculty of Health Sciences, Hokkaido University (Permission No. 15–90). The patient gave informed consent for participation of this study.

Consent for publication
The patient gave informed consent for publication of data.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 2Departments of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan. 3Hokkaido Renal Pathology Center, Sapporo, Japan. 4Faculty of Health Sciences, Hokkaido University, Kita-12, Nishi-5, Kita-ku, Sapporo 0600812, Japan. 5Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
References

1. Brinkmann V, Reichard U, Goosmann C, Fäulner B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5. https://doi.org/10.1126/science.1092385.

2. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood. 2009;114(3):2619–22. https://doi.org/10.1182/blood-2009-05-221606.

3. Doring Y, Weber C, Soehnlein O. Footprints of neutrophil extracellular traps as predictors of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2013;33(8):1735–6. https://doi.org/10.1161/ATVBAHA.113.301889.

4. Schreiber A, Rousselle A, Becker JU, von Massenhausen A, Linkermann A, Kettritz R. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc Natl Acad Sci U S A. 2010;107(21):9813–8. https://doi.org/10.1073/pnas.0909927107.

5. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107(21):9813–8. https://doi.org/10.1073/pnas.0909927107.

6. Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(11):3779–87. https://doi.org/10.1002/art.34619.

7. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955–63. https://doi.org/10.1172/JCI15918.

8. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115–9. https://doi.org/10.1073/pnas.90.11.4115.

9. Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol. 1991;50(6):539–46.

10. Kessenbrock K, Krumbholz M, Schonemarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.

11. Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25(5):990–7. https://doi.org/10.1681/ASN.2013060806.

12. Pendergraft WF 3rd, Niles IL, Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014;26(1):42–9. https://doi.org/10.1097/BOR.0000000000000144.

13. Kusunoki Y, Nakazawa D, Shida H, Hattanda F, Miyoshi A, Masuda S, et al. Peptidylarginine deiminase inhibitor suppresses neutrophil extracellular trap formation and MPO-ANCA production. Front Immunol. 2016;7(227) https://doi.org/10.3389/fimmu.2016.00227.

14. Magro CM, Mornhahen S, Harp J. The distinctive histopathology of hydralazine-associated ANCA positive vasculitis in vivo demonstration of NETosis. Eur J Dermatol. 2017;27(1):91–2. https://doi.org/10.1684/ejd.2016.2881.

15. Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123(4):1773–83. https://doi.org/10.1172/JCI65292.

16. Hakkim A, Fuchs TA, Martinez NE, Hess S, Prinz H, Zychlinsky A, et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol. 2011;7(2):75–8. https://doi.org/10.1038/ncmbio.496.

17. Desai J, Kumar SV, Mulyar SR, Konrad L, Romoli S, Schauer C, et al. PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling. Eur J Immunol. 2016;46(1):1223–9. https://doi.org/10.1002/eji.201545605.

18. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med. 2010;207(9):1853–62. https://doi.org/10.1084/jem.201000239.